Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialise OHB-607, a potentially transformative neonatal therapy

Chiesi Italy Austria Belgium France Germany Netherlands Spain Switzerland United Kingdom United States of America Massachusetts

Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate, to treat complications of extremely premature birth;This agreement expands Chiesi's commitment to Neonatology, a highly strategic area for the company;Partners intend to restart Phase 2b clinical trial of OHB-607 in 2024.View original content:https://www.prnewswire.co.uk/news-releases/chiesi-group-and-oak-hill-bio-announce-license-and-development-agreement-to-develop-manufacture-and-commercialise-ohb-607-a-potentially-transformative-neonatal-therapy-302028895.html